Clinical trials: Adenocarcinoma of the Prostate
NUT Midline Carcinoma, Triple Negative Breast Cancer
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Open-label, phase I, non-randomized, multicentric study of single-agent birabresib (MK-8628) (formerly known as OTX015) administered according to two distinct regimens to participants with selected advanced tumors.
- Conditions
- NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer
- Trial name
- NCT02259114
- Testing
- Birabresib
- Volunteers
- 47 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Prostate Adenocarcinoma
Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)
This study evaluates the possibility of patient-centered home care as a new model of cancer care to reduce disparities and improve health related quality of life and patient-reported outcomes in Black patients with prostate…
- Trial name
- NCT06470750
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Prostatic Neoplasms
A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate
This trial will evaluate, in patients with metastatic prostate cancer, the tolerability, toxicities, efficacy, and immunologic effects of repeated vaccinations with a recombinant vaccinia virus that contains the Prostate Specific…
- Trial name
- NCT00001382
- Testing
- PROSTVAC
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Conditions
- Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction
- Trial name
- NCT01434290
- Testing
- 36.25 Gy IMRT, 51.6 Gy IMRT
- Where
- 37 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- Radiation Therapy Oncology Group
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
This phase II trial studies the impact of 68GA-PSMA-11 positron emission tomography (PET)/computed tomography (CT) scan on treatment strategies for patients with prostate cancer.
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma
- Trial name
- NCT04050215
- Testing
- Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
- Where
- United States
- Volunteers
- 937 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Prostate Cancer
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, leuprolide, buserelin, and goserelin, may lessen the amount of androgens made by the body.
- Trial name
- DART (NCT00651326)
- Testing
- bicalutamide, buserelin, flutamide
- Where
- 13 sites in Canada
- Volunteers
- 48 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Adenocarcinoma, Stage I Prostate Cancer
Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer
The objective of this study is to examine how adenocarcinoma of the prostate treatment differentially affects African American men's ability to work and to describe and compare changes in work ability (as measured through…
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
- Trial name
- PCW (NCT03963739)
- Testing
- Interview, Questionnaire Administration
- Where
- 326 sites in United States, Guam
- Volunteers
- 255 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Prostate Adenocarcinoma
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer
To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.
- Trial name
- VERU-100 (NCT04843319)
- Testing
- VERU-100
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veru Inc.
Prostate Cancer
GM-CSF in Treating Patients With Relapsed Prostate Cancer
RATIONALE: Colony stimulating factors, such as GM CSF, may increase the number of immune cells found in bone marrow or peripheral blood.
- Trial name
- NCT00908141
- Testing
- sargramostim
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer, Prostate Adenocarcinoma
Active Surveillance for Low Risk Prostate Cancer
An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic…
- Trial name
- NCT04146077
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Prostate Cancer
Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin, may stop the adrenal glands from making androgens.
- Trial name
- NCT00423475
- Testing
- goserelin acetate, adjuvant therapy, radiation therapy
- Where
- 31 sites in France
- Volunteers
- 743 people
- Sponsor
- UNICANCER
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase I trial compares the effect of lutetium Lu 177 (177^Lu)-prostate-specific membrane antigen (PSMA)-617 in combination with Sipuleucel-T to 177^Lu-PSMA-617 alone in treating patients with prostate that has spread from…
- Trial name
- NCT07219147
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer, Prostate Adenocarcinoma
MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca
Phase II non-inferiority randomized trial of annual systematic biopsies versus mpMRI and targeted biopsies for men with low risk prostate cancer on active surveillance with any volume Gleason's Score 6, but no prior MRI imaging…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Multiparametric MRI, Gleason's Score 6
- Trial name
- NCT02564549
- Testing
- TRUS-guided biopsy, mpMRI with targeted biopsy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Virginia Commonwealth University
Male Erectile Disorder, Prostate Adenocarcinoma
Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer
This phase II trial studies how well pentoxifylline, atorvastatin, and vitamin E (PAVE) work in treating patients with erectile dysfunction after radiation therapy for prostate cancer. Atorvastatin may reduce high cholesterol.
- Conditions
- Male Erectile Disorder, Prostate Adenocarcinoma, Erectile Dysfunction, CTCAE, Impotence
- Trial name
- NCT03830164
- Testing
- Atorvastatin, Pentoxifylline, Vitamin E Compound
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
This phase II trial evaluates Fluorine-18 radiohybrid prostate-specific membrane antigen (18F- rhPSMA)-7.3 positron emission tomography (PET)/computed tomography (CT) scans with and without furosemide for the reduction of bladder…
- Trial name
- NCT05779943
- Testing
- Furosemide, F18-rhPSMA-7.3, Positron Emission Tomography
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Prostate Cancer
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer
RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well SB939 works in treating patients with recurrent or metastatic prostate…
- Trial name
- NCT01075308
- Testing
- HDAC inhibitor SB939
- Where
- 7 sites in Canada
- Volunteers
- 32 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T
This is a clinical research study of an investigational (FDA IND-BB 10091) treatment of subjects with castration-resistant prostate cancer resistant to Taxanes (docetaxel, cabazitaxel) and evidence of disease progression on…
- Trial name
- NCT01174368
- Testing
- Cancer Macrobead placement in abdominal cavity
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The Rogosin Institute
Prostate Adenocarcinoma
Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma
Patients with locally confined prostate adenocarcinoma (clinical stage T1c - T2bN0M0, Gleason score 7, PSA 20 ng/ml) are assigned to one of two treatment arms.
- Trial name
- NCT02339948
- Testing
- SBRT
- Where
- 4 sites in United States
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- GenesisCare USA
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the…
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04388852
- Testing
- Ipilimumab, Valemetostat
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center